Novo Nordisk to restrict starter dose supply for weight loss drug Wegovy
Faced with “all-time high levels” of new patients starting Novo Nordisk’s GLP-1 products, the company is temporarily restricting its supply of lower Wegovy dose strengths to “safeguard continuity of care,” according to EVP of North America operations Doug Langa.
The company will only be able to supply a limited amount of 0.25 mg, 0.5 mg and 1 mg doses to wholesalers for distribution to retail pharmacies which “will not meet anticipated patient demand,” a spokesperson told Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.